On May 27, 2022, Thomas Reilly, Chief Financial Officer of Cara Therapeutics, Inc. gave notice of his resignation, effective on or about June 15, 2022. Effective immediately following Mr. Reilly's departure, Richard Makara, the Company's Vice President, Head of Accounting & Controller, will assume Mr. Reilly's responsibilities on an interim basis. As of that date, Mr. Makara will assume the position of the Company's principal financial officer and principal accounting officer until such time as his successor is appointed, or until his earlier resignation or removal.

Mr. Makara, 52, has served the Company in various capacities since October 2014, most recently serving as VP, Head of Accounting & Controller from November 2018 to present. Mr. Makara previously served as the Company's principal financial officer and principal accounting officer on an interim basis from December 2019 to October 2020. Prior to joining the Company, he served as Director of Accounting at Purdue Pharma from June 2010 to October 2014.

Before joining Purdue, he served as an auditor for PricewaterhouseCoopers from 1992 to 2009. Mr. Makara received his B.S. in Accounting from Purdue University. Mr. Makara is a certified public accountant.